Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a report released on Friday. The firm issued a sell rating on the stock. MBRX stock opened at $1.89 on Friday. The company has a market cap of $54.01 million, a price-to-earnings ratio of -3.20 and a beta of 1.90. Moleculin Biotech […]

Related Keywords

,Morgan Stanley ,Moleculin Biotech Inc ,Goldman Sachs Group Inc ,Sigma Planning Corp ,Virtu Financial ,Moleculin Biotech Company Profile Get Rating ,Renaissance Technologies ,Moleculin Biotech ,Get Rating ,Planning Corp ,Goldman Sachs Group ,Xbiotech Company Profile ,Transcription Modulator ,Nasdaq Mbrx ,Ambrx ,Medical ,Initiated Coverage ,Stocknews Com ,